MALAKOFF, France--(BUSINESS WIRE)--Regulatory News:
THERACLION (ISIN: FR0010120402; Mnemo: ALTHE) (Paris:ALTHE), an innovative company developing a scalable robotic platform for non-invasive ultrasound therapy, today announced that 1000 patients suffering from varicose veins have been treated with the SONOVEIN®. These patients have received non-invasive echotherapy treatment in several centres in Europe and Asia, all led by key-opinion leaders in their field.
The SONOVEIN, CE marked in 2019, is the only non-invasive ablation therapy device for varicose veins. Since 1998, vascular doctors have been looking for alternatives to the endovenous thermal ablation. This device allows a treatment without the use of a catheter, chemical injections, or incisions, thus leaves no scars. The procedure can be performed in a non-sterile environment.
“Without doubt, over the next few years, non-invasive treatment of leg veins using High Intensity Focused Ultrasound, also called echotherapy, is going to have a major impact on the way that varicose veins and venous leg ulcers are treated by specialist doctors and clinics. I am delighted to be involved with this revolution in treatment” explains Prof. Whiteley, consultant venous surgeon and founder of The Whiteley Clinics, UK. “Despite being launched just as the Covid pandemic hit, the team at Theraclion has done an amazing job at supporting the development of this exciting non-invasive technique.” Prof. Whiteley, a renowned key opinion leader in varicose vein treatment has been an early adopter, using this disruptive technology since the CE mark of the 1st generation of the SONOVEIN.
Theraclion’s ambition is to revolutionize the $10 billioni varicose vein treatments and to give all patients access to non-invasive treatments.
As part of its strategy, Theraclion keeps exploring key partnership with significant corporate able to speed up the spread of its technology in the USA (seeking FDA clearance), in Europe and in Asia
Chronic Venous Insufficiency (CVI) and venous ulceration is a common health problem causing significant patient morbidity. Apart from the chronic physical and psychological disability caused to the individual, it also results in an enormous economic burden to the health care administration. Global prevalence rates of CVI are variable but may be as high as 40% among females and 17% among males1. Venous pathology generates around 5 million treatment procedures per year 2.
About Theraclion
At Theraclion we believe that surgery, as we know it, is outdated. It converts optimistic patients into anxious individuals, brilliant doctors into exhausted system executors and stretches healthcare systems to the limit. We have disrupted this convention by creating extracorporeal treatment platforms. We replace surgery with a robotic treatment from outside the body using High Intensity Focussed Ultrasound (HIFU). Our leading edge echotherapy platforms are currently CE marked in non-invasive treatment of varicose veins with SONOVEIN® and of breast fibroadenomas and thyroid nodules with Echopulse®.
Located in Malakoff, near Paris, our employees live and breath innovation by extensive clinical research and harness artificial intelligence. The market of varicose veins treatment alone requires around 5 million procedures annually. It is a dynamic market in which we change paradigms by making non-invasive echotherapy the new standard.
For more information, please visit www.theraclion.com and our patient website https://echotherapie.com/echotherapy/
Theraclion is listed on Euronext Growth Paris
Eligible for the PEA-PME scheme
Mnemonic: ALTHE - ISIN code: FR0010120402
LEI: 9695007X7HA7A1GCYD29
1 https://www.peertechz.com/articles/IJVSM-5-132.php
2 Millenium research Varicose Vein Device Market Study 2015
i Millenium research Varicose Vein Device Market Study 2015 | 2 Varicose veins – Felipe Collares